Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shortened treatment for smear-negative pulmonary tuberculosis with Mycobacterium vaccae immunotherapy
ChiCTR1900023398Phase 4Recruiting
- Sponsor
- Chinese Center for Disease Control and Prevention
- Start
- Jan 2019
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of mycobacterium vaccae in pulmonary tuberculosis (TB) (3 arms), sponsored by Chinese Center for Disease Control and Prevention. Primary endpoints: Absorption rate of lung lesions by chest X-ray, Incidence of adverse reactions and 6 more. Started Jan 2019; status: recruiting.
02
Drugs
mycobacterium vaccae
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on ChiCTR1900023398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023398.